TheraCryf PLC
Company Profile
Business description
TheraCryf PLC is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of unmet medical need within central nervous system (CNS) disorders. The Group's main programme is a novel, benchmark orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol, and other substance use disorders. It also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy, and narcolepsy. The Group also has an oncology programme in glioblastoma with SFX-01. It operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
9
Stocks News & Analysis
stocks
Why don’t good returns guarantee a 5-star rating?
stocks
Overvalued ASX share has overly ambitious profit target
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,997.30 | 168.10 | -1.83% |
| CAC 40 | 8,216.78 | 135.22 | -1.62% |
| DAX 40 | 26,045.37 | 553.27 | -2.08% |
| Dow JONES (US) | 50,759.42 | 848.75 | -1.64% |
| FTSE 100 | 10,689.87 | 191.68 | -1.76% |
| HKSE | 23,508.17 | 245.67 | -1.03% |
| NASDAQ | 24,328.38 | 181.38 | -0.74% |
| Nikkei 225 | 58,860.43 | 801.59 | -1.34% |
| NZX 50 Index | 14,348.64 | 41.68 | 0.29% |
| S&P 500 | 7,340.53 | 76.06 | -1.03% |
| S&P/ASX 200 | 8,883.20 | 161.50 | -1.79% |
| SSE Composite Index | 3,584.58 | 17.99 | -0.50% |